Euroapi S.A. operates in the healthcare sector, specifically focusing on the production of active pharmaceutical ingredients (APIs) across Europe. The company has a competitive position due to its extensive manufacturing capabilities in France and Germany, which allow it to serve a diverse range of pharmaceutical clients.
Euroapi generates revenue primarily through the production and sale of APIs, leveraging its advanced manufacturing facilities and regulatory compliance expertise. The company benefits from long-term contracts with major pharmaceutical companies, providing pricing power and stability in revenue streams.
Regulatory approvals for new APIs
Changes in pharmaceutical demand in Europe
Raw material cost fluctuations
Contract renewals with major clients
Regulatory changes impacting API production standards
Technological advancements in drug manufacturing
Emerging competitors in low-cost regions
Consolidation among pharmaceutical clients reducing demand
Low liquidity due to negative net margins
Potential pension obligations from workforce agreements
moderate - The demand for pharmaceuticals tends to be stable, but economic downturns can affect spending on non-essential drugs.
Low - Euroapi's business model is not heavily reliant on financing, but higher rates could impact capital expenditures.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on credit.
value - Investors may be drawn to Euroapi due to its low valuation metrics and potential for recovery.
high - The stock has shown significant volatility, particularly with a 1-year return of -58.6%.